>
MHCクラスI 複合体カスタムサービス
プロフェッショナルなMHC-ペプチド複合体の研究開発技術プラットフォーム
HEK293 発現系
さまざまなMHC I と抗原が利用可能
FITC/PE/APC/ビオチン標識を選択可能
成熟した生物活性検証プラットフォーム: SPR/ELISA/FACS など
MHCアレル | ターゲット | |
---|---|---|
HLA-A*0101 HLA-A*0201 HLA-A*0301 HLA-A*1101 HLA-A*2402 HLA-A*3303 HLA-B*1501 HLA-B*1525 HLA-B*3802 HLA-B*4601 HLA-B*0702 …… | NY-ESO-1 GP-100 MSLN AFP WT1 MAGE-A1 HPV HBV HIV EBV PRAME …… | ![]() |
分子名 | 製品番号 | 動物種 | 詳細 | 予約・注文する |
---|---|---|---|---|
HLA-A*0301 & B2M | HLM-H82W6 | Human | Biotinylated Human HLA-A*03:01&B2M Complex Protein (Peptide free, MALS verified) | |
HLA-A*02:01 & B2M | HLM-H82W3 | Human | Biotinylated Human HLA-A*02:01&B2M Complex Protein (Peptide free, MALS verified) | |
HLA-A*11:01 & B2M | HLM-H82W5 | Human | Biotinylated Human HLA-A*11:01&B2M Complex Protein (Peptide free, MALS verified) | |
HLA-A*0201 | B2M | EW | HLE-H82E4 | Human | Biotinylated Human HLA-A*02:01&B2M&EW (QLQNPSYDK) Complex Protein (Monomer) | |
HLA-A*0201 | B2M | AFP | HLA-H82E3 | Human | Biotinylated Human HLA-A*02:01&B2M&AFP (FMNKFIYEI) Complex Protein (Monomer, MALS verified) | |
HLA-A*0201 | B2M | TKI | HLT-H82E7 | Human | Biotinylated Human HLA-A*02:01&B2M&TKI (FLLTKILTI) Complex Protein (Monomer, MALS verified) | |
HLA-A*0201 | B2M | TRI | HLT-H82E9 | Human | Biotinylated Human HLA-A*02:01&B2M&TRI (FLLTRILTI) Complex Protein (Monomer, MALS verified) | |
HLA-A*02:01 & B2M & EW | HLE-H52E7 | Human | Human HLA-A*02:01&B2M&EW (QLQNPSYDK) Tetramer Protein | |
HLA-A*02:01 & B2M & WT-1 | HLW-H52E6 | Human | Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Tetramer Protein (MALS verified) | |
HLW-H82E5 | Human | Biotinylated Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Complex Protein (Monomer, MALS verified) | ||
HLA-A*02:01 & B2M & GP100 | HLG-H82E6 | Human | Biotinylated Human HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Complex Protein (Monomer, MALS verified) | |
HLA-A*0201 | B2M & HIV Gag | HLH-H82E8 | Human | Biotinylated Human HLA-A*02:01&B2M&HIV Gag (SLYNTVATL) Complex Protein (Monomer, MALS verified) | |
HLA-A*0201 | B2M | MAGE-A4 | HLM-H82E7 | Human | Biotinylated Human HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Complex Protein (Monomer, MALS verified) | |
HLA-C*07:02:01 & B2M & RYR | HLR-H52W2 | Human | Biotinylated Human HLA-C*07:02:01&B2M&RYR (RYRPGTVAL) Complex Protein (Monomer) | |
HLA-A*0201 | B2M & CMV pp65 | HLC-H82E4 | Human | Biotinylated Human HLA-A*02:01&B2M&CMV pp65 (NLVPMVATV) Complex Protein (Monomer, MALS verified) | |
HLA-A*0201 | B2M | HPV16-E6 | HLH-HP2H7 | Human | PE-Labeled Human HLA-A*02:01&B2M&HPV16-E6 (TIHDIILECV) Tetramer Protein | |
HLA-A*0201 | B2M | RHAMM-R3 | HLR-H82E6 | Human | Biotinylated Human HLA-A*02:01&B2M&RHAMM-R3 (ILSLELMKL) Complex Protein (Monomer, MALS verified) | |
HLA-A*02:01 & B2M & mage-a4 | HLM-H52E3 | Human | Human HLA-A*02:01&B2M&mage-a4 (GVYDGREHTV) Tetramer Protein | |
HLA-A*02:01 & B2M & NY-ESO-1 | HL1-H52E7 | Human | Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (MALS verified) | |
HL1-H52E8 | Human | Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein (MALS verified) | ||
HL1-H82E4 | Human | Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Complex Protein (Monomer, MALS verified) | ||
HL1-H82E6 | Human | Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein (Monomer, MALS verified) | ||
HLA-A*02:01 & B2M & RHAMM-R3 | HLR-H52E9 | Human | Human HLA-A*02:01&B2M&RHAMM-R3 (ILSLELMKL) Tetramer Protein | |
HLA-A*02:01 & B2M & Glycipan 3 | HLG-H52E5 | Human | Human HLA-A*02:01&B2M&Glycipan 3 (FVGEFFTDV) Tetramer Protein (MALS verified) | |
HLG-H82E4 | Human | Biotinylated Human HLA-A*02:01&B2M&Glycipan 3 (FVGEFFTDV) Complex Protein (Monomer, MALS verified) | ||
HLA-A*02:01 & B2M & Peptide (KVLEHVVRV) | HLK-H52E5 | Human | Human HLA-A*02:01&B2M&Peptide (KVLEHVVRV) Tetramer Protein (MALS verified) |
2e5 of NY-ESO-1 TCR-HEK293 cells (pool) were stained with PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) tetramer Protein(Fig B)and negative control protein respectively (Fig. A), and competitor-M represented competitor protein (Fig. C). PE signal was used to evaluate the binding activity
Anti-NY-ESO-1 antibody captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Biotinylated Human HLA-A0201 NY-ESO-1 (SLLMWITQC) Complex Protein (Cat. No. HL1-H82E6) with an affinity constant of 16.9 nM as determined in a SPR assay (Biacore 8K) (QC tested).
Anti-NY-ESO-1 antibody captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human HLA-A0201 NY-ESO-1 (SLLMWITQC) Tetramer Protein (Cat. No. HL1-H52E8) with an affinity constant of 1.35 nM as determined in a SPR assay (Biacore 8K) (QC tested).
1.Thomas C, Tampé R. MHC I assembly and peptide editing - chaperones, clients, and molecular plasticity in immunity. Curr Opin Immunol. 2021 Jun;70:48-56. doi: 10.1016/j.coi.2021.02.004. Epub 2021 Mar 6. PMID: 33689959.
2.Becar M, Kasi A. Physiology, MHC Class I. 2021 Sep 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 32310482.
This web search service is supported by Google Inc.